These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16121214)

  • 1. Antigen-specific cellular immunotherapy of leukemia.
    Van Driessche A; Gao L; Stauss HJ; Ponsaerts P; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Leukemia; 2005 Nov; 19(11):1863-71. PubMed ID: 16121214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
    Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
    Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms' tumor 1 as a novel target for immunotherapy of leukemia.
    Casalegno-Garduño R; Schmitt A; Wang X; Xu X; Schmitt M
    Transplant Proc; 2010 Oct; 42(8):3309-11. PubMed ID: 20970678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
    Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
    Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical peptide vaccination trials for leukemia patients.
    Casalegno-Garduño R; Schmitt A; Schmitt M
    Expert Rev Vaccines; 2011 Jun; 10(6):785-99. PubMed ID: 21692700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination for leukemia.
    Molldrem JJ
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):13-8. PubMed ID: 16399579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
    Sugiyama H
    Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen.
    Cebinelli GC; DE Sousa Pereira N; Sena MM; DE Oliveira CE; Fujita TC; DA Rocha SP; DE Abreu Oliveira FJ; Marinello PC; Watanabe MA
    Anticancer Res; 2016 Aug; 36(8):3795-802. PubMed ID: 27466479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
    Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
    Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
    Rosenfeld C; Cheever MA; Gaiger A
    Leukemia; 2003 Jul; 17(7):1301-12. PubMed ID: 12835718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system.
    Kanda T; Ochi T; Fujiwara H; Yasukawa M; Okamoto S; Mineno J; Kuzushima K; Tsurumi T
    Cancer Gene Ther; 2012 Aug; 19(8):566-71. PubMed ID: 22722376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural T cell immunity against cancer.
    Nagorsen D; Scheibenbogen C; Marincola FM; Letsch A; Keilholz U
    Clin Cancer Res; 2003 Oct; 9(12):4296-303. PubMed ID: 14555498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.
    Xue SA; Gao L; Thomas S; Hart DP; Xue JZ; Gillmore R; Voss RH; Morris E; Stauss HJ
    Haematologica; 2010 Jan; 95(1):126-34. PubMed ID: 19679884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.